Product Description
HT-004 is a potential disease-modifying agent that uses gene therapy-targeted methods to reduce mast cell responses to immunoglobulin E (IgE)-directed antigens, which is one of the key mechanisms in the pathophysiology of asthma, atopic dermatitis, and other allergic diseases. HT-004 is currently under investigation for treatment of asthma using inhalational administration. (Sourced from: https://ir.hoththerapeutics.com/ht-004)
Mechanisms of Action: FCER1 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoth Therapeutics
Company Location: Eastern America
Company CEO: Robb Knie
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Anaphylaxis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|